Table 1 Associations between clinical characteristics of HCC patients from TCGA and three immune subtypes
|  | Cluster1 (n = 104) | Cluster2 (n = 135) | Cluster3 (n = 132) | P-value |
|---|---|---|---|---|
Gender | Â | Â | Â | Â |
 Female | 33 (31.7%) | 42 (31.1%) | 46 (34.8%) | 0.788 |
 Male | 71 (68.3%) | 93 (68.9%) | 86 (65.2%) | |
Race | Â | Â | Â | Â |
 Asian | 52 (50.0%) | 52 (38.5%) | 54 (40.9%) | 0.116 |
 Black | 7 (6.7%) | 7 (5.2%) | 3 (2.3%) | |
 White | 42 (40.4%) | 74 (54.8%) | 68 (51.5%) | |
Alcohol consumption | 35 (33.7%) | 48 (35.6%) | 47 (35.6%) | 0.299 |
HBV | 63 (60.6%) | 84 (62.2%) | 82 (62.1%) | 0.172 |
HCV | 21 (20.2%) | 22 (16.3%) | 18 (13.6%) | 0.808 |
Drug treatment | 13 (12.5%) | 21 (15.3%) | 30 (22.5%) | 0.109 |
AFP | Â | Â | Â | Â |
 AFP < 200 | 47 (45.2%) | 70 (51.9%) | 84 (63.6%) | 0.018 |
 AFP > 200 | 31 (29.8%) | 19 (14.1%) | 27 (20.5%) | |
Vascular invasion | Â | Â | Â | Â |
 None | 46 (44.2%) | 74 (54.8%) | 86 (65.2%) | 0.057 |
 Yes | 38 (36.5%) | 33 (24.4%) | 38 (28.8%) | |
Tumor grade | Â | Â | Â | Â |
 G1 | 9 (8.7%) | 30 (22.2%) | 16 (12.1%) | 0.053 |
 G2 | 50 (48.1%) | 57 (42.2%) | 70 (53.0%) | |
 G3 | 40 (38.5%) | 43 (31.9%) | 39 (29.5%) | |
 G4 | 5 (4.8%) | 3 (2.2%) | 4 (3.0%) | |
T stage | Â | Â | Â | Â |
 T1 | 38 (36.5%) | 62 (45.9%) | 81 (61.4%) | 0.010 |
 T2 | 34 (32.7%) | 36 (26.7%) | 24 (18.2%) | |
 T3 | 28 (26.9%) | 31 (23.0%) | 21 (15.9%) | |
 T4 | 4 (3.8%) | 5 (3.7%) | 4 (3.0%) | |
M stage | Â | Â | Â | Â |
 M0 | 75 (72.1%) | 92 (68.1%) | 99 (75.0%) | 0.215 |
 M1 | 1 (1.0%) | 0 (0%) | 3 (2.3%) | |
 MX | 28 (26.9%) | 43 (31.9%) | 30 (22.7%) | |
N stage | Â | Â | Â | Â |
 N0 | 69 (66.3%) | 84 (62.2%) | 99 (75.0%) | 0.103 |
 N1 | 2 (1.9%) | 2 (1.5%) | 0 (0%) | |
 NX | 32 (30.8%) | 49 (36.3%) | 33 (25.0%) | |
Pathological stage | Â | Â | Â | Â |
 Stage I | 36 (34.6%) | 57 (42.2%) | 78 (59.1%) | 0.002 |
 Stage II | 32 (30.8%) | 32 (23.7%) | 22 (16.7%) | |
 Stage III | 32 (30.8%) | 31 (23.0%) | 22 (16.7%) | |
 Stage IV | 1 (1.0%) | 1 (0.7%) | 3 (2.3%) |